Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Free Cash Flow: 2019-2025

Historic Free Cash Flow for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -$27.3 million.

  • Kymera Therapeutics' Free Cash Flow rose 45.42% to -$27.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.2 million, marking a year-over-year decrease of 55.34%. This contributed to the annual value of -$207.3 million for FY2024, which is 51.01% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Free Cash Flow stood at -$27.3 million, which was up 54.95% from -$60.6 million recorded in Q2 2025.
  • Kymera Therapeutics' Free Cash Flow's 5-year high stood at -$3.6 million during Q4 2023, with a 5-year trough of -$79.6 million in Q1 2025.
  • Moreover, its 3-year median value for Free Cash Flow was -$47.6 million (2024), whereas its average is -$46.6 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Free Cash Flow soared by 91.03% in 2023, and later crashed by 1,651.96% in 2024.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' Free Cash Flow stood at -$38.9 million in 2021, then declined by 2.72% to -$39.9 million in 2022, then skyrocketed by 91.03% to -$3.6 million in 2023, then tumbled by 1,651.96% to -$62.7 million in 2024, then surged by 45.42% to -$27.3 million in 2025.
  • Its Free Cash Flow stands at -$27.3 million for Q3 2025, versus -$60.6 million for Q2 2025 and -$79.6 million for Q1 2025.